A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma

  • End date
    Jul 28, 2023
  • participants needed
  • sponsor
    Incyte Corporation
Updated on 21 October 2022
myelodysplastic syndromes
multiple myeloma
chronic myelomonocytic leukaemia


This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

Condition Myelodysplastic Syndromes, Multiple Myeloma, Anemia
Treatment INCB000928
Clinical Study IdentifierNCT04582539
SponsorIncyte Corporation
Last Modified on21 October 2022


Yes No Not Sure

Inclusion Criteria

Agreement to avoid pregnancy or fathering children
Participants who are transfusion-dependent or present with symptomatic anemia
For MDS participants
Ineligible to receive or have not responded to available therapies for anemia such as ESAs or lenalidomide
Not requiring cytoreductive therapy other than hydroxyurea
BM and peripheral blood myeloblast count < 10%
Histologically confirmed diagnosis of the MDS, CMML and unclassifiable MDS/MPN overlap syndromes
For MM participants
Histologically confirmed diagnosis of MM
After failure of available standard treatments such as alkylating agents, glucocorticoids, immunomodulatory drugs (lenalidomide,pomalidomide, or thalidomide), proteasome inhibitors (bortezomib or carfilzomib), and daratumumab

Exclusion Criteria

Any prior allogeneic stem cell transplantation or a candidate for such transplantation
Any major surgery within 28 days before the first dose of study drug
Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, or antibody or hypomethylating agent to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug
Undergoing treatment with another investigational medication or having been treated with an investigational medication within 28 days before the first dose of study drug. -Undergoing treatment with ESAs, granulocyte colony-stimulating factor or granulocyte/macrophage colony-stimulating factor, romiplostin, or eltrombopag at any time within 28 days before the first dose of study drug
Undergoing treatment with a strong or potent inhibitor or inducer of CYP3A4/5 within 28 days or 5 half-lives (whichever is longer) before the first dose of study drug or expected to receive such treatment during the study
History of clinically significant or uncontrolled cardiac disease
History or presence of an abnormal ECG that, in the investigator's opinion, is clinically Meaningful
Presence of chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment
Diagnosis of chronic liver disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note